Globalization and generic drugs: There's a collection of news today that illustrates a couple of trends that have taken firm hold in the drug-sales world, two trends that are inextricably linked.
Sanofi-Aventis has made a $2 billion bid for Czech generic drugmaker Zentiva. The offer will compete with an earlier bid by finance group PPF--Sanofi is offering 10 percent more than the group,
Pfizer and Ranbaxy have come to an agreement that will end most of their five-year battle over the generic production of Lipitor, the world's best-selling drug. Ranbaxy will have a license to sell
Can Shire weather the upcoming loss of Adderall XR to the off-patent wildnerness? Company execs say it can: They point out that 60 percent of the company's revenues derive from other products. And
Just two years ago, Wal-Mart started its program to sell a select list of generic prescription
Ethypharm S.A., Takeda Pharmaceutical Co. and TAP Pharmaceuticals Inc. are suing Barr Pharmaceuticals Inc. for patent infringement, Barr confirmes. The suit is over Barr's plan to market a generic
Here's a turnabout-is-fair-play story. Generics maker Teva Pharmaceuticals, known for its aggressive challenges to brand-name drugs, is getting challenged itself. The company has one very big branded
The Federal Trade Commission is none too happy with Big Pharma's dealmaking with generics companies. Drugmakers are using legal settlements with copycat manufacturers to keep cheaper meds off the
Wyeth is going toe-to-toe with Novartis. The Protonix maker-- and its partner, Nycomed-- filed suit against Novartis' generics arm, saying its copycat drug violates the heartburn med's U.S.
New data on pharma sales details some big shifts in spending. Diabetes meds have displaced cholesterol drugs as the leading drivers of spending growth, for one thing; generic competition is reining